What are the recommended management strategies for hot flashes in a man being treated with darolutamide (Nubeqa) for non‑metastatic castration‑resistant prostate cancer?

Management of Hot Flashes in Men on Darolutamide (Nubeqa)

First-Line Pharmacologic Treatment

Start with gabapentin 300 mg daily, titrating to 900 mg daily as tolerated, as this is the preferred non-hormonal agent recommended by NCCN for hot flashes in men receiving androgen deprivation therapy. 1, 2

Non-Hormonal Pharmacologic Options (Preferred)

• Gabapentin is the first-line choice, demonstrating a 46% reduction in hot-flash severity at 8 weeks compared to 15% with placebo in randomized controlled trials. 1
• Venlafaxine 37.5 mg daily (may increase to 75 mg daily) is an acceptable alternative, reducing hot-flash frequency by 61% in men on ADT. 1, 2
• Paroxetine 10-12.5 mg daily reduced composite hot-flash scores by 62-65% in pilot studies and represents another SSRI option. 1, 2

Clinical Rationale for Gabapentin Priority

• Gabapentin addresses both hot flashes and commonly concurrent symptoms including sleep disturbances and neuropathic pain, making it particularly advantageous in this population. 1
• The side effect profile is favorable compared to hormonal alternatives, with lower discontinuation rates than agents like clonidine (which has a 40% discontinuation rate). 1

Hormonal Rescue Therapy (Second-Line)

Reserve hormonal therapies for patients who fail to respond to non-hormonal agents after 4-6 weeks at maximal tolerated doses. 1, 2

• Medroxyprogesterone acetate (MPA) is the NCCN-recommended hormonal rescue option when gabapentin, venlafaxine, or paroxetine prove ineffective. 1
• Transdermal estradiol represents an alternative hormonal therapy for refractory hot flashes with demonstrated efficacy in men on ADT. 1, 2
• Cyproterone acetate is listed as another hormonal rescue option for persistent vasomotor symptoms. 1, 2, 3

Critical Contraindications

• Testosterone replacement is absolutely contraindicated in men with advanced prostate cancer receiving darolutamide and ADT, as emphasized by NCCN guidelines. 1, 2
• Avoid vitamin E supplements due to concerns about increased prostate cancer risk in this population. 1, 2

Agents to Avoid

• Clonidine provides only modest benefit (46% reduction) with high discontinuation rates (40%) due to adverse effects; NCCN advises against routine first-line use. 1
• Phytoestrogens, botanicals, and dietary supplements are classified as category 2B (insufficient evidence) and are not recommended. 1

Evidence-Based Non-Pharmacologic Interventions

Implement these concurrently with pharmacologic management to optimize symptom control:

• Cognitive-behavioral therapy (CBT) reduced the perceived burden of hot flashes in a controlled trial of 68 men on ADT. 1, 2
• Acupuncture shows reduction in hot-flash frequency in small studies and is listed as a supportive option by NCCN. 1, 2
• Exercise/physical activity and yoga are recommended as adjunctive measures to improve vasomotor symptoms and quality of life. 1, 2
• Lifestyle modifications including weight loss in overweight/obese patients, maintaining a cool environment, and wearing layered clothing help lessen hot-flash severity. 1, 2
• Hypnosis is recognized as a potential complementary technique for symptom control. 1

Alternative ADT Strategies for Severe Refractory Symptoms

• Discuss intermittent ADT with the oncologist when hot flashes are severely disruptive and refractory to all pharmacologic interventions. 1
• Anti-androgen monotherapy represents another strategy to mitigate vasomotor symptoms while maintaining oncologic control. 1

Clinical Context Specific to Darolutamide

• Darolutamide has a favorable tolerability profile with adverse events similar to placebo, including a low incidence of ARi-associated side effects. 4, 5, 6
• Hot flashes occur in 50-80% of men receiving ADT (which is continued with darolutamide), making proactive management essential for quality of life. 1
• The incidence of adverse events with darolutamide remained low and similar to placebo even with extended treatment, with 98.8% of patients receiving the full planned dose. 6
• Discontinuation rates due to adverse events were only 8.9% with darolutamide versus 8.7% with placebo, indicating excellent overall tolerability. 4

Common Pitfalls to Avoid

• Do not discontinue ADT when managing hot flashes, as maintaining castrate testosterone levels (<50 ng/dL) is essential for oncologic control. 7
• Do not delay treatment of hot flashes; early intervention with gabapentin improves adherence and quality of life. 1
• Do not use testosterone under any circumstances in this population, despite its effectiveness for hot flashes in other contexts. 1, 2